Drug Profile
LAE 001
Alternative Names: CFG-920; LAE001Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Laekna Therapeutics; Novartis
- Class Antineoplastics; Chlorinated hydrocarbons; Imidazolines; Pyridines; Small molecules
- Mechanism of Action Aldosterone synthase inhibitors; Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 21 Feb 2024 Laekna Therapeutics suspends a phase I/II trial in Prostate cancer (Metastatic disease, Hormone refractory) in China (PO) due to change in clinical development plan (NCT03843918)
- 20 Oct 2023 Updated safety and efficacy data from the phase I/II combination trial in Cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 17 May 2022 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in South Korea (PO) (NCT04060394)